Latest News- Biologics Contract Development And Manufacturing Organization (CDMO) Market: Mammalian is expected to lead the Type segment during 2025-2029

The Biologics Contract Development And Manufacturing Organization (CDMO) Market is being driven by Availability of cost-efficient resources in emerging markets

The Biologics Contract Development And Manufacturing Organization (CDMO) Market is expected to grow at a CAGR of 13.7% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 16324.6 million. In the rapidly evolving pharmaceutical landscape, the application of advanced analytics has become a game-changer for both drug research and development. With the drug development process being intricate and time-consuming, the integration of data analytics tools is streamlining the clinical data synthesis process. One such strategy gaining traction is the utilization of big data, which is revolutionizing decision-making within the healthcare industry, including pharmaceuticals. Data analytics plays a pivotal role in identifying promising new drug candidates, creating simulation models to predict drug efficacy, determining target patient populations, and monitoring potential side effects. By leveraging these insights, Biologics Contract Development and Manufacturing Organizations (CDMOs) can enhance their capabilities, ensuring the production of safe and effective therapies. 

Get more information on Biologics Contract Development And Manufacturing Organization (CDMO) Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Type
  • Mammalian
  • Microbial
• Product Type
  • Biologics
  • Biosimilars
• Service
  • CMO
  • CRO
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
    • France
    • Italy
  • Asia
    • China
    • India
    • Japan
    • South Korea
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Availability of cost-efficient resources in emerging markets
• Strong research and development pipeline of biologics therapeutics
• Growing need to focus on core competencies

However, the market also witnesses some limitations, which are as follows:

• Capacity utilization and constraints
• Stringent policies related to entry of new biologics
• Serialization issues faced by CDMOs due to multiple production lines

Benefits of Buying Global Biologics Contract Development And Manufacturing Organization (CDMO) Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Biologics Contract Development And Manufacturing Organization (CDMO) Market Research Report

Request Free Sample

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Biologics CDMO market caters to the production of large molecules, including biologics, monoclonal antibodies, cancer therapies, biosimilars, and small molecules for chronic infectious diseases. Pharma clients rely on these organizations for clinical services, process engineering, automation, and software development in the biology sector. Tissue processing and quality testing are essential components of the supply chain for diabetes patients and small-molecule drugs in the biopharmaceutical industry.

Market Research Overview

The Biologics Contract Development and Manufacturing Organization (CDMO) market is a significant segment within the larger pharmaceuticals industry. This market encompasses entities specializing in the production of small molecules, large molecules, including biologics, biosimilars, cancer therapies, and monoclonal antibodies. The growth of this sector is driven by several factors, such as the increasing demand for advanced technology, the rising prevalence of chronic diseases, and the need for efficient supply chain solutions. Third-party logistic providers play a crucial role in ensuring the seamless delivery of these complex products. Quality testing and regulatory compliance are essential components of the CDMO value proposition. Technavio, a leading market research firm, projects that the global pharmaceuticals market, which includes manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services, will experience significant growth due to demographic trends, such as an aging population. By 2050, approximately one-quarter of the US and European populations are projected to be over 60 years old. This demographic shift will create increased demand for healthcare products and services, including biologics and other complex therapeutics.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/